Description: Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its lead product is Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion. The company is also developing NNZ-2591 that is in preclinical development for the treatment of various neurological disorders. In addition, it holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand.
Home Page: www.neurenpharma.com
697 Burke Road
Camberwell,
VIC
3124
Australia
Phone:
61 3 9092 0480
Officers
| Name | Title |
|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 15.6006 |
|---|---|
| Trailing PE: | 12.6984 |
| Price-to-Book MRQ: | 4.748 |
| Price-to-Sales TTM: | 5.7645 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |